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Introduction
Congenital muscular dystrophies (CMDs) represent a clinically 
and molecularly heterogeneous group of autosomal recessive 
neuromuscular disorders with a typical early onset of symp-
toms. Estimates in Italy suggest an incidence rate of 4.65 × 
10
−5 (Mostacciuolo et al., 1996). Thus, after Duchenne muscu-
lar dystrophy (DMD), CMDs represent the second most fre-
quent neuromuscular disorder. Laminin-α2–defi  cient  CMD, 
classifi  ed as MDC1A, accounts for  30–40% of all CMD pa-
tients. MDC1A is a severe progressive muscle-wasting disease 
that leads to death in early childhood (Miyagoe-Suzuki et al., 
2000; Muntoni and Voit, 2004; Ruegg, 2005). It shows a rather 
homogenous clinical picture, with severe neonatal hypotonia 
associated with joint contracture and inability to stand or walk. 
Moreover, MDC1A is accompanied by a peripheral neuropathy 
that is caused by demyelination in the peripheral and central 
nervous system. However, no mental retardation is observed in 
most patients.
Laminins are cruciform-like molecules formed by α, β, 
and γ chains (Fig. 1 A). There are 5 α, 3 β, and 3 γ chains de-
scribed so far that give rise to 15 isoforms (Aumailley et al., 
2005). The central role of laminins can be explained by their 
dual function in organizing a structured basement membrane 
through interaction with other basement membrane proteins 
and connecting basement membranes to adjacent cells via cell 
surface receptors. Inactivation of different laminin chains in 
mice causes distinct phenotypes (for review see Miner and 
Yurchenco, 2004). The laminin-α2 chain assembles to laminin-211 
(LM-211; α2, β1, and γ1) and LM-221. LM-211 is the main 
isoform in the basement membrane of muscle and peripheral 
nerve, whereas laminin-221 is restricted to neuromuscular junc-
tions (Patton et al., 1997). In the basement membrane, LM-211 
and -221 bind to other laminins, to nidogen (which in turn binds 
to collagen IV and perlecan), and to agrin (Fig. 1 A). The self-
polymerization activity of LM-211 is thought to be p  articularly 
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utations in laminin-α2 cause a severe congeni-
tal muscular dystrophy, called MDC1A. The 
two main receptors that interact with laminin-α2 
are dystroglycan and α7β1 integrin. We have previously 
shown in mouse models for MDC1A that muscle-speciﬁ  c 
overexpression of a miniaturized form of agrin (mini-
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span and improves overall health, although not to the 
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protein containing the dystroglycan-binding domain of 
perlecan has the same activities as mini-agrin in amelio-
rating the disease. Finally, expression of full-length agrin 
also slows down the disease. These experiments are 
  conceptual proof that linking the basement membrane 
to dystroglycan by speciﬁ  cally designed molecules or 
by endogenous ligands, could be a means to counteract 
MDC1A at a progressed stage of the disease, and thus 
opens new possibilities for the development of treatment 
options for this muscular dystrophy.
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important for the formation of a proper muscle basement 
  membrane. The main receptors for laminin-α2 in adult muscle 
are dystroglycan and α7β1 integrin (Fig. 1 A, green). Dystro-
glycan is cleaved into the peripheral α-dystroglycan and the 
transmembranous β-dystroglycan. In the membrane, dystro-
glycan associates with the sarcoglycans and sarcospan and 
  intracellularly binds to dystrophin, which in turn links the 
complex to the f-actin cytoskeleton. The complex between 
LM-211, dystroglycan, sarcoglycans, and dystrophin, which is 
called the dystrophin–glycoprotein complex (DGC), has been 
shown to be of utmost importance for the maintenance of 
muscle integrity, as mutations in these components cause dif-
ferent types of muscular dystrophies (for review see Davies 
and Nowak, 2006). Similarly, mice or humans that are defi  cient 
of α7 integrin display a mild muscular dystrophy (Mayer et al., 
1997; Hayashi et al., 1998), and muscle-specifi  c inactivation 
of β1 integrins has a major impact on muscle development 
(Schwander et al., 2003). Thus, the evidence is strong that both 
receptor systems contribute to the linking of basement mem-
brane to the f-actin cytoskeleton, and it is likely that the two 
systems act synergistically.
MDC1A is among the most severe muscle dystrophies, 
which may be based on the observation that the absence of lam-
inin-α2 leaves both receptor systems unoccupied by its ligand. As 
a compensatory mechanism, muscle fi  bers of MDC1A patients 
and laminin-α2–defi  cient mice increase synthesis of   laminin-α4 
(Patton et al., 1997; Ringelmann et al., 1999; Moll et al., 2001; 
Bentzinger et al., 2005). However, LM-411 is truncated at the 
N-terminal end, which prevents its self-polymerization, and it 
also does not bind to α-dystroglycan or α7β1 integrin with 
high affi  nity (Kortesmaa et al., 2000; Talts et al., 2000). There is 
also evidence that muscle fi  ber membranes of MDC1A patients, 
and mice models thereof, contain signifi  cantly lower levels of 
α7β1 integrin (Vachon et al., 1997) and α-dystroglycan (Moll 
et al., 2001; Bentzinger et al., 2005). In addition, the ability of 
muscle to regenerate is greatly impaired (Kuang et al., 1999; 
Bentzinger et al., 2005). These defi  ciencies lead to the dystrophic 
phenotype characterized by high levels of creatine kinase (CK) in 
the blood, large variation in fi  ber size, successive replacement of 
muscle by fi  brous tissue, and infi  ltration of adipose tissue. Good 
models for the disease are dy
W/dy
W mice generated by homo-
logous recombination (Kuang et al., 1998). Like human patients, 
dy
W/dy
W mice have an early onset and severe dystrophic pheno-
type, which is often lethal between 6 and 16 wk. They grow at 
a slow rate, the histology of muscles is very similar to that of 
  human patients, and they have a prominent peripheral neuropathy 
based on defective myelination of the peripheral nerve.
There is no curative treatment for MDC1A. However, a 
“replacement therapy” using a miniaturized form of the base-
ment membrane component agrin (mini-agrin) was shown to 
markedly lower muscle degeneration and mortality in dy
W/dy
W 
mice (Moll et al., 2001). This is caused by both increasing the 
tolerance to mechanical load and improving the regenerative 
capability of the muscle (Bentzinger et al., 2005). These stud-
ies left several questions unanswered that were addressed in 
the current study. First, an effi  cacious treatment also needs to 
work after the onset of the disease. Second, a requisite to envis-
age pharmacological treatment options that aim at increasing 
synthesis of endogenous agrin is to show that full-length agrin 
can also have a benefi  cial effect. Finally, although it is highly 
suggestive that the benefi  cial effect of mini-agrin is based on 
the linking of the up-regulated LM-411 with α-dystroglycan 
Figure 1.  Interactions of laminin-211 and 
scheme of constructs used in the study. 
(A) Structure and binding sites of LM-211. Lam-
inins form by coiled-coil interactions of α, β, 
and γ chains. Interactions of LM-211 and -221 
with extracellular matrix components are indi-
cated in red and italics. The main receptors 
are indicated in green and include different 
  integrins and α-dystroglycan. (B and C) Sche-
matic representation of nonneuronal agrin 
(B) and perlecan (C). Domain structures and 
abbreviations are adopted from previous stud-
ies (Bezakova and Ruegg, 2003; Iozzo, 
2005). The domains included in the constructs 
used in this study are color-coded, and relevant 
binding partners are indicated. (D) Schematic 
presentation of constructs used in the study. 
Promoters (green), domains (see color code in 
B and C), and tags are indicated for each con-
struct. MCK represents the 1.3-kb fragment of 
the human MCK promoter. TetO7-CMV repre-
sents the tetracycline-responsive promoter (Fig. 
S1 A). Fig. S1 is available at http://www.jcb
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(Moll et al., 2001), other mechanisms (e.g., via integrins) may 
also contribute.
In an attempt to answer these open questions, we prepared 
a panel of constructs to generate different transgenic mouse lines 
(Fig. 1, B–D). First, we used the tet-off system (Fig. S1 A, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200611152/DC1) 
to generate dy
W/dy
W mice in which expression of mini-agrin 
can be temporally controlled (Gossen and Bujard, 1992). Se-
cond, we generated transgenic dy
W/dy
W mice that overexpress 
chick full-length muscle agrin (c-FLag) in muscle (Fig. 1, B and D). 
Third, we generated dy
W/dy
W mice that overexpress a fusion 
construct in which we replaced the α-dystroglycan binding re-
gion of chick mini-agrin (c-mag) with that of mouse perlecan 
(AgPerl; Fig. 1, C and D). Domain V of perlecan (also called 
endoreppelin; Iozzo, 2005) binds to α-dystroglycan (Talts et al., 
1999), but not to integrins that are expressed in muscle. In this 
study, we show that mini-agrin can slow down the progression 
of MDC1A at any stage of the disease, full-length agrin is capa-
ble of improving muscle function, and the fusion construct 
between agrin and perlecan also counteracts the disease. In 
summary, our results are conceptual proof that linkage of lam-
inin isoforms with α-dystroglycan is a means to treat MDC1A 
also at progressed stages of the disease.
Results
The most important questions for developing a treatment are to 
determine the effi  cacy of therapy at a progressed stage of the 
disease, to establish a molecular understanding of how the treat-
ment interferes with disease progression, and to establish possi-
ble routes of applying the treatment. To this end, we generated 
a set of transgenic animals that overexpress artifi  cially designed 
proteins in skeletal muscle. All the constructs, including their 
promoters, are listed in Fig. 1 D.
Tight spatial and temporal regulation 
of mini-agrin expression
To test whether mini-agrin is also capable of ameliorating the 
disease when the phenotype is already apparent, we generated 
mice in which expression of mini-agrin can be controlled by 
 removal of doxycycline (Gossen and Bujard, 1992). To minimize 
immune responses and for detection, we constructed mini-agrin 
from mouse cDNA and fused a c-myc tag to its C terminus (Fig. 
1 D). Like c-mag, the tagged mouse mini-agrin (m-mag) bound 
to LM-111 and α-dystroglycan (Fig. S2, available at http://
www.jcb.org/cgi/content/full/jcb.200611152/DC1). Double 
transgenic mice in which expression of m-mag could be con-
trolled by doxycycline (Gossen and Bujard, 1992; Ghersa et al., 
1998) were generated (for details see Fig. 1 D, Fig. S1, and 
  Materials and methods). When they were examined for the ex-
pression of m-mag, the highest levels on the mRNA and protein 
level were detected in line L3 (Fig. 2, A and B; Table I for quan-
tifi  cation) which was used in all further experiments. Expres-
sion of m-mag was highest in skeletal muscle and heart, whereas 
only little or no m-mag was detected in liver, lung, kidney, or 
brain (Fig. 2 C). Next we determined the concentration of doxy-
cycline needed to suppress expression of m-mag throughout 
embryonic development and to allow fast induction. We found 
that 5 μg/ml doxycycline in the drinking water of pregnant and 
gestating females was suffi  cient to completely inhibit m-mag 
transcription (Fig. 2 D) and translation (Fig. 2, E and F). 3 d 
after withdrawal of doxycycline, m-mag was already expressed 
at high levels, and it reached a maximum after 6 d (Fig. 2, D–F; 
Table I for quantifi  cation).
Figure 2.  Expression of m-mag in transgenic lines. (A) Northern 
blot analysis of quadriceps and (B) immunostaining of triceps 
brachii cross sections from transgenic mouse lines 1–4 (L1–L4) 
and WT mice. Highest expression of m-mag mRNA ( 3.6 kb) 
and protein was detected in L3. (C) Western blot analyses 
from different tissues of L3. High levels of m-mag ( 130 kD) 
were detected in skeletal muscle (triceps brachii) and the heart. 
Very low levels of m-mag were observed in liver and kidney, 
but not in lung or brain. (D–F) Expression of m-mag in mouse 
line L3 is regulated by doxycycline. 5 mg/l doxycycline (Dox) 
in the drinking water suppresses the expression of m-mag at the 
transcriptional (D) and protein level (E and F). After withdrawal 
of doxycycline for 3 d (wd 3d), m-mag is detected, and levels 
similar to nontreated transgenic mice (no Dox) can be reached 
after 6 d (wd 6d). Note the lower molecular weight protein 
bands in (C and F), which are indicative of proteolytic degra-
dation/processing. For normalization, probes for β-actin were 
used in Northern blot analyses (A and D) and antibodies 
against β-tubulin and -actin in Western blots (C and F). For quan-
tiﬁ  cation see Table I. Bars, 50 μm.JCB • VOLUME 176 • NUMBER 7 • 2007  982
Late onset of mini-agrin expression 
ameliorates disease progression 
in dy
W/dy
W mice
To generate laminin-α2–defi  cient mice that allowed controlling 
expression of m-mag, we mated line L3 with mice heterozygous 
for the laminin-α2 mutation. This breeding eventually resulted 
in dy
W/dy
W mice that contained all the necessary genetic ele-
ments (see Fig. S1 B for the breeding scheme). In such mice, 
which are called dy
W/m-mag, we removed doxycycline at birth, 
which resulted in expression of m-mag at postnatal day 3 
(henceforth called dy
W/m-mag 3d), at day 11 (dy
W/m-mag 14d), 
or at day 25 (dy
W/m-mag 28d). Muscular dystrophy was always 
evaluated in 4- and 6-wk-old mice. In a grip test, dy
W/m-mag 
mice always performed better than dy
W/dy
W controls, irrespec-
tive of when expression of m-mag was started (Fig. 3 A). In the 
4- and 6-wk-old animals the improvement was less pronounced 
if m-mag expression was started late (dy
W/m-mag 28d). In an 
open fi  eld test, locomotory activity in 4-wk-old m-mag trans-
genic mice was signifi  cantly higher than in dy
W/dy
W mice, 
whereas in 6-wk-old mice, statistical signifi  cance could only be 
reached in mice expressing the transgene early (Fig. 3 B). To get 
a direct measure for ongoing muscle fi  ber damage, we mea-
sured the CK activity in the blood (Fig. 3 C). CK activity was 
 5 times higher in dy
W/dy
W than in wild-type (WT) mice. Ex-
pression of m-mag lowered CK activity in dy
W/dy
W mice by ap-
proximately half (Fig. 3 C). In contrast to the behavioral tests, 
the lowering of the CK activity was not dependent on when 
mini-agrin expression started. Although the improvement in the 
capability of moving is certainly important to determine the 
benefi  t of a treatment, the strongest endpoint in such a severe 
disease is life expectancy. As shown in Fig. 3 D, treatment that 
started only after 4 wk substantially increased survival proba-
bility. In accordance with this, the mean lifespan of dy
W/m-mag 
28d mice was approximately tripled compared with dy
W/dy
W 
mice (Fig. 3 E).
Another hallmark of the severe muscular dystrophy in 
dy
W/dy
W mice is the presence of many small fi  bers and of fi  brotic 
tissue as visualized by hematoxylin and eosin (HE, Fig. 4 A) 
and Masson’s Trichrome staining (Fig. 4 B) of cross sections 
from triceps brachii. In 6-wk-old dy
W/dy
W mice, muscle showed 
strong signs of degeneration and replacement of muscle with 
nonmuscle tissue (Fig. 4 A, top right). The nonmuscle cells 
Figure 3.  Mini-agrin improves overall performance, lowers 
muscle damage, and prolongs lifespan. Parameters were 
measured in 4- or 6-wk-old WT, laminin-α2–deﬁ  cient (dy
W/
dy
W), and laminin-α2–deﬁ  cient mice expressing m-mag (dy
W/
m-mag) or c-mag (dy
W/c-mag). (A) In grip strength, all 
mini-agrin–expressing mice show a signiﬁ  cant improvement 
compared with dy
W/dy
W mice. The improvement is less in mice 
expressing mini-agrin late (dy
W/m-mag 14d or dy
W/m-mag 
28d). (B) Locomotive activity within 10 min. In 4-wk-old mice, 
all mini-agrin–expressing mice show a signiﬁ  cant  improve-
ment compared with dy
W/dy
W mice. In 6-wk-old mice, only 
early treatment (dy
W/c-mag and dy
W/m-mag 3d) is signiﬁ  -
cant. (C) CK levels in the blood. All values are normalized to 
WT mice. CK activity is reduced to approximately half of that 
measured in dy
W/dy
W mice in all mini-agrin–expressing mice, 
irrespective of the onset of expression. (D and E) Survival 
curves of mice with different genotypes. Late start of mini-agrin 
expression (dy
W/m-mag 28d) increases the survival probabil-
ity (D; n ≥ 29) and the mean survival (E; n ≥ 16) more than 
twice in comparison to dy
W/dy
W mice. Note that late expres-
sion of mini-agrin is signiﬁ  cantly less effective than constitutive 
expression of c-mag (dy
W/c-mag mice). All values represent 
the mean ± the SEM. n ≥ 3. P-values (t test) are as follows: 
**, P < 0.01; *, P < 0.05; ns (not signiﬁ  cant), P > 0.05.
Table I. Quantiﬁ  cation of mRNA and protein levels of m-mag in dif-
ferent transgenic lines, and induction by withdrawal of doxycycline
Line Dox NB WB IHC
L1 65 63 ± 12 70 ± 8
L2 40 57 ± 14 68 ± 3
L3 100 100 ± 7 100 ± 4
L4 1 3 ± 15  ± 2
L3 Dox 1 0 1 ± 1
L3 wd 3d 72 92 ± 6 56 ± 7
L3 wd 6d 102 96 ± 9 97 ± 6
Quantiﬁ  cation of Northern blot analysis (NB), immunohistochemistry (IHC), and 
Western blot analysis (WB). Values show expression levels of m-mag in skeletal 
muscles of mouse lines L1–L4. Data of line L3 after suppression of expression 
by doxycycline (Dox) and subsequent withdrawal for 3 (wd 3d) or 6 d (wd 6d) 
are relative to levels measured in mouse line L3. Values represent the mean ± 
the SEM. n ≥ 3.AMELIORATION OF LAMININ-𝗂2 DEFICIENCY • MEINEN ET AL. 983
represented mainly fi  brotic tissue, as suggested by the blue 
color in the Masson’s Trichrome staining (Fig. 4 B). Moreover, 
muscle fi  bers in dy
W/dy
W mice often lost their characteristic 
  polygonal shape, which is indicative of impaired nerve conduc-
tion. Although expression of the m-mag transgene prevented 
much of the fi  brosis (Fig. 4, A and B), it did not affect the shape 
of the muscle fi  bers. The extent of fi  brosis depended on the time 
point of the transgene expression. It was, however, compelling 
that a treatment of only 2 wk was still suffi  cient to improve the 
histological picture of the muscle. To measure these parameters 
more quantitatively, we determined the muscle fi  ber size distri-
bution in 4-wk- (not depicted) and 6-wk-old mice (Fig. 4 C). 
Compared with WT mice, the fi  ber size distribution was obvi-
ously shifted toward smaller fi  bers in dy
W/dy
W mice, as many 
did not exceed a minimal diameter of 15 μm (Fig. 4 C). This 
shift was prevented by the expression of m-mag. To quantify 
 fi brosis, we determined fi  rst the relative percentage of the area 
covered by nonmuscle tissue in a series of muscle cross sec-
tions. As shown in Fig. 4 D, expression of the m-mag transgene 
prevented the fi  brotic phenotype of dy
W/dy
W muscle to a great 
extent. As an independent measure of fi  brosis, we also deter-
mined the amount of hydroxylated proline in muscles of the dif-
ferent genotypes (Fig. 4 E). Hydroxyproline is a main constituent 
of collagens whose expression is high in fi  brotic tissue. This 
quantifi  cation also showed the benefi  cial effect of m-mag. In 
contrast to the counting of nonmuscle tissue, the amount of hy-
droxyproline was at least twice as high in all mini-agrin trans-
genic dy
W/dy
W mice compared with WT controls, and this increase 
was independent of the time point of expression (Fig. 4 E).
Several lines of evidence strongly indicate that muscles 
of MDC1A patients, and animal models thereof, have a reduced 
capacity of regenerating upon damage (Miyagoe et al., 1997; 
Kuang et al., 1999). In dy
3K/dy
3K mice, another mouse model 
for MDC1A, this pathology is reversed by constitutive expres-
sion of mini-agrin (Bentzinger et al., 2005). To test whether the 
onset of expression of m-mag infl  uences the outcome of the re-
generation process, we induced degeneration by injection of 
notexin into the tibialis anterior muscle of dy
W/m-mag 28d 
mice 1 wk after induction of the mini-agrin. Muscles were then 
examined 6, 14, and 28 d after injection and compared with 
WT and dy
W/dy
W mice. As shown in Fig. 5 A, 6 d after injec-
tion, many muscle fi  bers had already reformed in both WT and 
dy
W/m-mag 28d mice. Indicative of ongoing regeneration, these 
muscle fi  bers expressed high levels of developmental myosin 
heavy chain (dMyHC; Fig. 5 B). In contrast, muscle of dy
W/dy
W 
mice contained mainly cells with a very small cytoplasmic sur-
round and only a few dMyHC-positive fi  bers (Fig. 5, A and B). 
The difference between dy
W/dy
W and WT or dy
W/m-mag 28d 
mice was highly signifi  cant in the quantitative assessment of 
the fi  ber size distribution (Fig. 5 C). 14 d after notexin injec-
tion, the muscle fi  ber size had further increased, and fi  bers 
no longer expressed dMyHC in both WT and dy
W/m-mag 
28d mice (Fig. 5 A). Myonuclei still had a central position, which 
was indicative of the recent regeneration (Fig. 5 A, arrows). 
Figure 4.  Phenotype analysis in triceps 
brachii muscle of 6-wk-old mice. HE (A) 
and Masson’s Trichrome (B) staining of 
cross sections. Pathological changes in the 
muscle of dy
W/dy
W mice, i.e., ﬁ  brosis, vari-
ation in muscle ﬁ  ber diameters, inﬁ  ltration of 
nonmuscle tissue, and collagen-containing 
tissue (blue in B), are less pronounced in 
mice expressing mini-agrin, but are de-
pendent on the time point of mini-agrin ex-
pression. Note that mini-agrin expression 
does not prevent appearance of polygo-
nally shaped muscle ﬁ  bers. (C) Muscle ﬁ  ber 
size distribution. Values represent relative 
numbers of ﬁ  bers in a given diameter class. 
Muscle ﬁ  bers of dy
W/dy
W mice are signiﬁ  -
cantly smaller than age-matched ﬁ   bers 
of dy
W/dy
W mice expressing mini-agrin. 
(D) Relative contribution of ﬁ  brotic regions 
to the total area in cross sections. In 6-wk-old 
dy
W/dy
W mice, the ﬁ  brotic tissue represents 
>30% of the entire muscle. In all the mini-
agrin transgenic dy
W/dy
W mice, the ﬁ  bro-
sis is signiﬁ   cantly reduced. (E) Relative 
amount of hydroxyproline (OH-Pro) in mus-
cles of the different genotypes. The amount 
of OH-Pro is signiﬁ  cantly reduced by mini-
agrin (dy
W/m-mag 3d and 14d, >50%; 
dy
W/m-mag 28d, >30%). Values represent 
the mean ± the SEM. n ≥ 3. P-values (t test) 
are as follows: **, P < 0.01; *, P < 0.05; 
ns, P > 0.05. Bar, 50 μm.JCB • VOLUME 176 • NUMBER 7 • 2007  984
In contrast, cross sections from dy
W/dy
W mice contained large 
regions with mononucleated cells (Fig. 5 A, arrowheads), and 
the few muscle fi  bers did not express dMyHC (Fig. 5 B). This 
defi  ciency in regenerative capacity of dy
W/dy
W mice was also 
eminent in the fi  ber size distribution (not depicted). 4 wk after 
notexin injection, muscles had almost completely recovered. 
Figure 5.  Expression of mini-agrin enhances regeneration of skeletal muscle after notexin-induced injury of tibialis anterior muscle. Notexin injection was 
performed in 5-wk-old mice in which mini-agrin expression had been started 1 wk before. Muscles were analyzed 6 (A and B, notexin 6d; C), 14 (A and B, 
notexin 14d), and 28 d (A and B, notexin 28d; D–F) after injection. (A) HE-stained cross sections. (B) Staining with the nuclear marker DAPI (blue), anti-
bodies to dMyHC (green), and laminin-γ1 (red) were used to determine the state of regeneration. 6 d after notexin injection, muscle ﬁ  bers are regenerating 
in WT and dy
W/m-mag 28d mice, while regeneration is poor in dy
W/dy
W mice; this is indicated by large regions containing mononucleated cells (arrow-
heads). 14 d after notexin injection, dy
W/dy
W muscle still contains many mononucleated cells (arrowhead) and little dMyHC is expressed. In WT and dy
W/
m-mag 28d mice, regeneration has progressed and most of the muscle ﬁ  bers have lost expression of dMyHC. 28 d after notexin injection, muscle is restored 
in WT and dy
W/m-mag 28d, although centralized nuclei are still present. In dy
W/dy
W mice, large regions of the muscle fail to regenerate and are replaced 
by nonmuscle tissue. (C) Fiber size distribution 6 d after notexin injection. Quantiﬁ  cation of ﬁ  brosis (D) and ﬁ  ber size distribution 28 d after injection (E). 
There is a signiﬁ  cant difference between dy
W/dy
W mice and the other two genotypes. (F) HE staining of longitudinal sections of muscles 28 d after notexin 
injection. Dy
W/dy
W muscle is characterized by extensive ﬁ  brosis, and most of the remaining muscle ﬁ  bers are smaller and thinner than in the other two genotypes. 
Values represent the mean ± the SEM. n ≥ 3. P-values (t test) are as follows: **, P < 0.01; *, P < 0.05; ns, P > 0.05. Bars, 50 μm.AMELIORATION OF LAMININ-𝗂2 DEFICIENCY • MEINEN ET AL. 985
Muscle of dy
W/dy
W mice still contained large regions that were 
reminiscent of fi  brotic tissue (see Fig. 5 D for quantifi  cation), 
and the diameter of the muscle fi  bers was often <15 μm (Fig. 
5 E). To see whether the regenerated muscle fi  bers spanned the 
entire length of the muscle, we also examined longitudinal sec-
tions of tibialis anterior muscle. In contrast to WT mice, most 
of the regenerated muscle fi  bers were rather short and thin, and 
large parts of the muscle of dy
W/dy
W mice still contained mono-
nucleated cells (Fig. 5 F). Muscle from dy
W/m- mag 28d and 
WT mice showed a homogenous fi  ber size distribution and only 
little fi  brosis. These experiments show that mini-agrin is suffi  -
cient to restore the regenerative capacity of muscle from dy
W/dy
W 
mice to almost WT levels. Importantly, 1 wk of m-mag expression 
is suffi  cient for this effect.
We have previously shown that constitutive overexpres-
sion of mini-agrin in dy
W/dy
W mice leads to increased levels of 
laminin-α5 and α-dystroglycan (Moll et al., 2001), and that this 
is based on posttranscriptional effects (Bentzinger et al., 2005). 
The protein levels of laminin-α5 were also increased in all dy
W/
m-mag mice, irrespective of the onset of m-mag expression 
(Fig. S3 A, available at http://www.jcb.org/cgi/content/full/
jcb.200611152/DC1; and Table II). Similarly, using antibodies 
directed to the core protein (Herrmann et al., 2000), we found 
increased levels of α-dystroglycan in all the transgenic mice 
(Fig. S3 A; Table II). In contrast, we could not detect any 
changes in the levels of α7 integrin (not depicted), which is in 
agreement with earlier fi  ndings (Moll et al., 2001). Because re-
cent experiments showed that transgenic expression of laminin-α1 
is highly benefi  cial in dy
3K/dy
3K mice (Gawlik et al., 2004), we 
also stained for this laminin chain. Basement membranes sur-
rounding skeletal muscle did not contain detectable levels of 
laminin-α1 (Fig. S3 B), which is consistent with published 
  results (Patton et al., 1997). Our data thus show that an increase 
in the amount of laminin-α1 is unlikely the mechanism of how 
mini-agrin ameliorates the disease in dy
W/dy
W mice.
Full-length agrin or an agrin-perlecan fusion 
protein ameliorate disease progression
Another treatment option for MDC1A patients is the up-regulation 
of the expression of endogenous agrin in muscle, similar to 
what has been proposed for utrophin in DMD patients (for re-
view see Miura and Jasmin, 2006). Because full-length agrin is 
a large, highly glycosylated protein, its effi  cacy in ameliorating 
the disease might differ from mini-agrin. To test this, we gener-
ated transgenic mice that overexpress c-FLag in muscle (Fig. 1, 
B and D). In another set of experiments, we wanted to test our 
initial hypothesis that the benefi  cial effect of mini-agrin is based 
on the linking of the up-regulated laminin isoforms containing 
laminin-α4 to α-dystroglycan (Moll et al., 2001) and not to the 
integrins. To this end, we generated a fusion construct in which 
we replaced the 95-kD, C-terminal half of agrin with domain V/
endorepellin of mouse perlecan (Fig. 1, C and D). Like mini-
agrin, this fusion protein (AgPerl) bound to α-dystroglycan 
(Fig. S2 C). These data are consistent with the fi  nding that 
Figure 6.  Transgenic expression of c-FLag and an AgPerl fusion protein improves muscle function and lifespan in dy
W/dy
W mice. (A) Immunostaining of 
transgenes in triceps brachii muscle of transgenic mouse lines for c-FLag (L2, L4, and L9) or AgPerl (L1, L2, L4, and L5). L4 (c-FLag L4) and L1 (AgPerl L1) ex-
press the highest levels for c-FLag and AgPerl fusion construct, respectively. For quantiﬁ  cation see Table III. Improvement in locomotion (B) or CK values in 
the blood (C) is evident for all the transgenic mice at an age of 4 wk. (D and E) Life expectancy. The survival probability (D; n ≥ 29) and the mean survival 
(E; n ≥ 23) are more than doubled in the transgenic compared with the dy
W/dy
W mice. Note that in most of the parameters measured there is a trend that 
the amelioration is less pronounced in dy
W/c-FLag mice than in dy
W/c-mag or dy
W/AgPerl mice. Values in all quantiﬁ  cations represent the mean ± the 
SEM. n ≥ 3. P-values (t test) are as follows: **, P < 0.01; *, P < 0.05; ns, P > 0.05. Bar, 50 μm. 
Table II. Quantiﬁ  cation of laminin-𝗂5 and 𝗂-dystroglycan detected 
at the membrane of triceps brachii
Strain Laminin-𝗂5 𝗂-Dystroglycan
WT 100 ± 17 100 ± 13
dy
W/dy
W 138 ± 9 27 ± 6
dy
W/c-mag 373 ± 33 71 ± 14
dy
W/m-mag 3d 365 ± 17 64 ± 18
dy
W/m-mag 14d 409 ± 17 61 ± 10
dy
W/m-mag 28d 368 ± 16 63 ± 17
Expression levels of laminin-α5 and α-dystroglycan were compa-
rable in dy
W/c-mag and dy
W/m-mag mice starting expression in 
advanced stages of the disease. Values are relative to WT mice and 
represent the mean ± the SEM. n ≥ 3.JCB • VOLUME 176 • NUMBER 7 • 2007  986
 domain V/endorepellin  binds  to  α-dystroglycan with similar af-
fi  nity as laminin-α2 (Talts et al., 1999) or agrin (Gesemann 
et al., 1998).
Between the different mouse lines, the mRNA levels of 
the transgenes varied substantially, whereas the amount of pro-
tein detected in muscle was similar (Fig. 6 A; Table III). To as-
sess the capability of the transgenes to ameliorate the disease in 
dy
W/dy
W mice, the mouse lines with the highest expression lev-
els were crossbred and analyzed (i.e., c-Flag L4 and AgPerl 
L1). In the locomotory test, all the transgenic lines showed a 
highly signifi  cant improvement compared with dy
W/dy
W mice 
(Fig. 6 B). Moreover, CK levels in the blood were signifi  cantly 
lower (Fig. 6 C). Most importantly, the survival probability and 
the mean survival of the transgenic mice were higher than in 
dy
W/dy
W mice (Fig. 6, D and E).
Muscle histology was substantially improved as shown by 
HE staining of triceps brachii from 4-wk-old mice (Fig. 7 A), 
and the size distribution of the muscle fi  bers was shifted to 
larger fi  bers (Fig. 7 B). Consistent with the hypothesis that the 
mechanism of amelioration by the transgenes is the same as in 
mini-agrin transgenic mice, protein levels for both laminin-α5 
and α-dystroglycan were elevated (Fig. 7 C; Table IV for quanti
fi  cation). Our experiments thus show that full-length agrin and 
a fusion protein of agrin and perlecan ameliorate the disease 
phenotype in dy
W/dy
W mice. In most measurements, mice ex-
pressing the AgPerl transgene showed a better improvement 
than those expressing c-FLag.
If human patients were to be treated, an appropriate route 
of application must be defi  ned. Such routes for mini-agrin could 
be viral vectors (Qiao et al., 2005), but also injection of recom-
binant protein, as done for other muscle diseases (Bogdanovich 
et al., 2002; Raben et al., 2003). To test the feasibility of protein 
application, we determined the turnover rate of mini-agrin in 
our mouse model. To this end, mice were raised in the presence 
of doxycycline (i.e., m-mag not expressed), followed by 1 wk 
without doxycycline (m-mag expressed). Thereafter, doxy-
cycline was reapplied and m-mag expression was followed on 
the mRNA and the protein level over time. 1 d after readdition 
of doxycycline, the mRNA encoding mini-agrin had already 
dropped to  10%, and it could not be detected anymore after 
2 d (Fig. 8 A). Concomitantly, with the repression of transcrip-
tion, m-mag protein steadily declined, as determined by Western 
blot analysis (Fig. 8 B) and immunohistochemistry (Fig. 8 C). 
Quantifi  cation of the amount of mini-agrin after suppression of 
its transcription indicates a half-life of 4.5 d (Fig. 8 D).
To get an estimate of how high the levels of agrin must be 
to achieve an improvement, we compared the levels of endoge-
nous mouse agrin found in other tissues to the levels of the 
transgenes expressed in muscles of our mice. We fi  rst compared 
the levels of the transgenic protein for mini- and full-length 
agrin using antibodies that recognize chick, but not mouse, 
agrin (Fig. 8 E, left column). The amount of c-mag was  20% 
higher than c-FLag (Fig. 8 F; left column). We then compared 
staining intensity of the transgenic m-mag in muscle with that 
for endogenous agrin in kidneys using antibodies directed to 
mouse agrin (Fig. 8 E, right column). Expression levels of the 
transgenic m-mag were 13% lower than the levels of endoge-
nous agrin detected in kidney (Fig. 8 F, right columns). To com-
pare levels of endogenous agrin in kidney and the amount of 
c-FLag in muscle, we assumed that the amount of c- and m-mag 
were the same. This assumption is based on the fact that the 
overall improvement in the phenotype is the same in dy
W/c-mag 
and dy
W/m-mag mice. Expression levels of c- and m-mag trans-
genes were therefore set as being equal. Based on this, the pro-
tein level of the transgenic c-FLag (81% of c-mag) is substantially 
lower than the amount of endogenous agrin found in kidney 
(113% of m-mag). Thus, expression levels of endogenous agrin 
in kidney are even substantially higher than the levels of the 
transgenic c-FLag in the muscle. Thus, agents that increase the 
amount of agrin in muscle to the amount in kidney are suffi  cient 
to be of benefi  t for dy
W/dy
W mice.
Discussion
In our previous work (Moll et al., 2001; Bentzinger et al., 2005), 
we provided in vivo evidence that mini-agrin could be a means 
to prevent muscular dystrophy in MDC1A patients. The work 
described in this study approaches both therapeutic and mecha-
nistic aspects of how mini-agrin ameliorates the phenotype in 
dy
W/dy
W mice. It provides strong evidence that mini-agrin also 
decelerates disease progression when applied at late stages, and 
it shows that full-length agrin, if expressed at a level similar to 
that in kidney, is capable of ameliorating the disease. Finally, 
our evidence that the fusion construct between the laminin-
binding domain of agrin and the α-dystroglycan–binding do-
main of perlecan has the same ameliorating activity in dy
W/dy
W 
Table III. Quantiﬁ  cation of mRNA levels by Northern blot analysis (NB) and protein levels by immunohistochemistry (IHC) or Western blot 
analysis (WB) in different transgenic lines expressing c-FLag or AgPerl
Strain Line NB WB IHC
c-mag 100 100 ± 6 100 ± 5
c-FLag L2 57 89 ± 19 84 ± 6
L4 63 97 ± 10 87 ± 5
L9 42 67 ± 24 78 ± 9
AgPerl L1 210 79 ± 2 84 ± 5
L2 72 70 ± 5 78 ± 6
L4 42 69 ± 1 87 ± 3
L5 50 60 ± 9 85 ± 6
Values show the expression in skeletal muscles of c-FLag in mouse lines L2, L4, and L9 and of AgPerl in mouse lines L1, L2, L4, and L5. Data are relative to levels 
measured in mice transgenic for c-mag (Moll et al., 2001). Values represent the mean ± the SEM. n ≥ 3.AMELIORATION OF LAMININ-𝗂2 DEFICIENCY • MEINEN ET AL. 987
mice as mini-agrin clearly indicates that the amelioration is 
based on the linking of muscle basement membrane to the DGC, 
and not to integrins.
Mini-agrin slows down MDC1A 
disease progression
In MDC1A patients, the disease is often diagnosed in the fi  rst 
year of life because of the fl  oppy appearance of the infants. How-
ever, muscular dystrophy has already started to manifest at the 
time of diagnosis, and treatment of infants faces diffi  culties. 
Therefore, it is important to evaluate the potential of mini-agrin 
treatment at progressed stages of the disease. To test this, we 
generated dy
W/dy
W mice that allow the temporal control of the 
expression of mini-agrin in muscle using the tet-off system (Gossen 
and Bujard, 1992; Ghersa et al., 1998). We show that mini-agrin 
is of clear, but attenuated, benefi  t when applied at progressed 
disease stages. Importantly, expression of mini-agrin after 4 wk, 
when the disease is already far progressed, still tripled the mean 
survival. Our evidence indicates that mini-agrin mainly acts on 
the tissue that has not yet been destroyed in the course of the dis-
ease. This is best manifested by the fi  nding that late expression 
of mini-agrin seems not to affect already existing fi  brosis (Fig. 4), 
and that early treatment is superior in the behavioral tests (Fig. 3, 
A and B). There is also evidence that the time point of transgene 
expression is not relevant for parameters that measure acute 
  responses, such as CK activity in the blood (Fig. 3 C) or the 
  regeneration upon injury (Fig. 5). Our experiments are thus evi-
dence that even late application of mini-agrin is highly benefi  cial, 
but that treatment is most successful if initiated early.
Mini-agrin combines several advantages 
for a feasible treatment of MDC1A patients
Our proof-of-concept experiment using transgenic mice is a 
crucial step toward devising ways of treating MDC1A patients. 
Similar to mini-agrin, transgenic expression of laminin-α1 
also improves muscle function (Gawlik et al., 2004). Although 
this approach may be interesting for therapy, the use of  laminin-α1 
seems less feasible than that of mini-agrin. First, the size of 
its cDNA (>9 kb) prevents its packaging into AAV vectors. 
Second, laminin-α1 must also become incorporated into the 
laminin heterotrimer to be functional, which makes it diffi  cult 
to generate a miniaturized version of laminin-α1 because 
Figure 7.  Characterization of muscles from mice 
transgenic for c-FLag or the AgPerl fusion protein. 
Animals were analyzed at 4 wk of age. (A) HE 
staining of triceps brachii cross sections. (B) Mus-
cle ﬁ  ber size distribution. Values are given as rela-
tive number of ﬁ   bers in each diameter class. 
Muscles of dy
W/dy
W mice contain a signiﬁ  cantly 
higher percentage of small ﬁ   bers. (C) Levels of 
laminin-α5 (left column) and α-dystroglycan (right 
column) are increased in muscles of dy
W/c-FLag or 
dy
W/AgPerl mice relative to dy
W/dy
W mice. See 
Table IV for quantiﬁ  cation. Values in all quantiﬁ  ca-
tions represent the mean ± the SEM. n ≥ 3. P-  values 
(t test) are as follows: **, P < 0.01; *, P < 0.05; 
ns, P > 0.05. Bars, 50 μm.
Table IV. Quantiﬁ  cation of laminin-𝗂5 and 𝗂-dystroglycan in triceps 
brachii of dy
W/dy
W mice expressing dy
W/c-FLag or dy
W/AgPerl
Strain Laminin-𝗂5 𝗂-Dystroglycan
WT 100 ± 16 100 ± 11
dy
W/dy
W 138 ± 20 28 ± 3
dy
W/c-FLag 263 ± 64 60 ± 6
dy
W/AgPerl 266 ± 39 61 ± 6
dy
W/c-mag 264 ± 40 69 ± 12
Both transgenes increase the concentration of laminin-α5 and α-dystroglycan in 
dy
W/dy
W mice. Similar values were observed in dy
W/c-mag mice. Values are 
relative to WT mice and represent the mean ± the SEM. n ≥ 3.JCB • VOLUME 176 • NUMBER 7 • 2007  988
 several  domains contribute to its functionality. In contrast, 
mini-agrin combines several advantages, and thus might be a 
promising strategy for the treatment of MDC1A patients. As 
the next step will be the defi  ning of a route of application, we 
determined the half-life of mini-agrin in the transgenic mice. 
We found that it was  4.5 d, which is substantially less than 
what has been estimated for full-length agrin when injected 
into rat muscle (Bezakova et al., 2001). One of the reasons for 
this difference could be the lack of any O-glycosylation in 
mini-agrin. Moreover, mini-agrin also seems to be targeted by 
proteases of unknown identity, as the protein displays distinct 
bands in Western blots (Moll et al., 2001; this study). Never-
theless, the good stability of mini-agrin, in combination with 
the fact that it acts extracellularly, makes it a valuable candidate 
gene for gene therapy. Indeed, recent experiments in dy
W/dy
W 
mice showed that transduction of skeletal and heart muscle by re-
combinant adeno-associated virus that express mini-agrin restored 
muscle function (Qiao et al., 2005; Meinen and Ruegg, 2006). 
An alternative way of treating patients might also be the 
use of recombinant protein and its targeting to the affected 
tissue. Examples for the successful targeting of recombinant 
enzymes and antibodies to muscle are the treatment of lyso-
somal storage diseases (Desnick, 2004) and muscle wasting 
(Bogdanovich et al., 2002), respectively. The major obstacle 
for mini-agrin’s reaching muscle is, however, its laminin-
  binding, as laminins line the endothelial wall of blood vessels 
(Hallmann et al., 2005). Thus, it will be important to reduce 
the size of the injected protein (e.g., the binding of agrin to 
α-dystroglycan requires only two laminin G–like domains) 
and to apply enhancers of endothelial permeability, such as 
VEGF or histamine.
Up-regulation of endogenous agrin provides 
an alternative treatment option
An alternative treatment option is the use of molecules that 
  increase the expression of the endogenous agrin protein in 
Figure 8.  Feasibility for the use of mini-agrin or up-
  regulation of endogenous agrin expression as a treatment 
option. (A–D) Stability of mini-agrin in skeletal muscle of 
4-wk-old transgenic mice. (A) Time course of m-mag tran-
scripts in triceps brachii after repression by 50 mg/liter 
doxycycline in the drinking water, as determined by quan-
titative real-time PCR. After 2 d, m-mag transcripts cannot 
be detected anymore. Concomitantly, mini-agrin protein is 
lost from the muscle basement, as determined by Western 
blot analysis from quadriceps (B) and quantitative immuno-
staining of cross sections from triceps brachii muscle (C). 
(D) Quantitative immunohistochemistry indicates a half-
life of mini-agrin protein of  4.5 d. Values are expres-
sed as percentages of staining relative to values before 
suppression by doxycycline. (E) Staining of transgenic 
c-mag and c-FLag (left) in triceps brachii muscle using anti-
bodies recognizing chick, but not mouse agrin. Staining 
using antibodies against mouse agrin in triceps brachii 
muscle of mice transgenic for m-mag or in kidneys of WT 
mice (WT kidney; right). Note that staining in green (left) 
detects only the transgenes, whereas staining in red (right) 
can detect both the m-mag and endogenous agrin. (F). 
Quantiﬁ  cation of staining intensity. Protein expression lev-
els of c-FLag reach 81% of c-mag (left). Endogenous agrin 
expression in kidney is 13% higher than the levels of trans-
genic m-mag in muscle (right). For details see the text and 
the Materials and methods. Values represent the mean ± 
the SEM. n ≥ 3. Bar, 50 μm. AMELIORATION OF LAMININ-𝗂2 DEFICIENCY • MEINEN ET AL. 989
MDC1A patients. In mdx mice, which are mouse models of 
DMD, up-regulation of the endogenous utrophin, which is the 
autosomal homologue of dystrophin, has been shown to amelio-
rate the dystrophic phenotype (Miura and Jasmin, 2006). Re-
cently, intraperitoneal injection of a peptide derived from 
heregulin was shown to increase expression of utrophin and 
thereby ameliorate the disease in mdx mice (Krag et al., 2004). 
We show that c-FLag, indeed, ameliorates the disease and pro-
longs lifespan in dy
W/dy
W mice. This is experimental proof that 
the aforementioned strategy might be promising for the treat-
ment of MDC1A patients. We found that the improvement with 
c-FLag is less effective than with mini-agrin. This difference 
might arise from a distinct orientation of the domains important 
for laminin and α-dystroglycan binding caused by the size dif-
ference or differences in glycosylation. Full-length agrin is  95 nm 
long (Denzer et al., 1998), whereas mini-agrin folds into a 
  globular structure with an estimated length of 20 nm. Moreover, 
the high carbohydrate content of full-length agrin may impose 
a different orientation of the two functional domains, and the 
presence of heparan sulfate glycosaminoglycan side chains may 
lower its apparent binding affi  nity to α-dystroglycan, as binding 
of agrin to α-dystroglycan is inhibited by heparin (Gee et al., 
1994; Gesemann et al., 1996). Finally, the amount of full-length 
agrin expressed in our transgenic mice is lower than that of 
mini-agrin. However, the difference in the protein concentration 
between the two transgenes became smaller the older the mice 
were (unpublished data). Thus, it is likely that the slow turnover 
rate of full-length agrin in the basement membrane allows it to 
accumulate over time and to eventually reach saturation, despite 
being less strongly expressed. Accumulation of agrin would be 
highly desirable in a pharmacological approach because even a 
moderate increase in agrin transcripts would then result in high 
concentrations of the protein over time. Moreover, the levels of 
transgenic agrin necessary for its ameliorative effect are even 
lower than those found in kidney. Thus, such an approach may 
indeed be feasible.
A mechanistic explanation 
of agrin’s activity
We also provide conceptual proof that mini-agrin’s benefi  cial 
effect on the disease progression in dy
W/dy
W mice arises from 
the reconnection of muscle basement membrane with the cyto-
skeleton via the DGC, as a chimeric fusion protein between 
  AgPerl has the same effi  cacy in ameliorating the disease as 
mini-agrin. Both mini-agrin and AgPerl bind to laminins and 
α-dystroglycan, and they compete for the same binding sites 
(unpublished data). Our experiments therefore indicate that 
  integrins do not contribute to the ameliorating activity because 
the C-terminal proportions of AgPerl bind to different integrins 
(Brown et al., 1997; Burgess et al., 2002). In addition, the α2β1 
integrin receptor of domain V/endorepellin is not even ex-
pressed in muscle. Our model that reconnection of laminins and 
α-  dystroglycan is the underlying mechanism for the benefi  cial 
 effect  of  mini-agrin and AgPerl is also corroborated by the 
fact that CMDs with phenotypes similar to those of MDC1A 
are based on mutations in glycosyltransferases that have 
α-  dystroglycan as their main substrates (Muntoni and Voit, 2004).
One of the most striking fi  ndings is that mini-agrin, ir-
respective of the onset of its expression, increases the regene ra tive 
capacity of muscle fi  bers in dy
W/dy
W mice. After notexin-induced 
muscle damage, many fi  bers in the WT and the dy
W/m-mag 
mice regenerate within the fi  rst week, as indicated by the ex-
pression of dMyHC. In contrast, in dy
W/dy
W mice, dMyHC was 
expressed only marginally in the early phase, but was also not 
up-regulated later. Moreover, muscle fi  bers that had formed in 
dy
W/dy
W mice were shorter, and the muscle contained large re-
gions with mononucleated cells (Fig. 5). This is evidence that 
muscle regeneration in dy
W/dy
W mice is not simply delayed, 
but that some of the crucial steps cannot be accomplished. The 
mechanism behind how LM-211 infl  uences regeneration is not 
known. For example, expression of LM-211 in satellite cells 
themselves may improve proliferation or survival. Alterna-
tively, satellite cells may depend on LM-211 bound to muscle 
basement membrane for adhesion and/or survival, which, in 
turn, would allow their fusion. These events may even be in-
terdependent, as muscle fi  bers are known to undergo detach-
ment- induced apoptosis, which is termed anoikis, during 
regenera  tion (Kuang et al., 1999). The fact that only 1 wk of 
mini-agrin expression can restore muscle regeneration to lev-
els indistinguishable from WT mice suggests that its binding 
to α-dystroglycan may activate pathways that prevent anoikis. 
Indeed, disruption of the binding of laminin with α-dystroglycan 
induces cell death in cultured muscle cells because of the per-
turbation of the phosphoinositide 3-kinase–protein kinase B 
pathway. Thus, we favor a mechanism in which mini-agrin 
bound to muscle basement membranes allows the survival of 
satellite cells and early myotubes.
We also fi  nd that the level of laminin-α5, but not laminin-α1, 
is increased in all mice that express a transgene. The increase in 
laminin-α5 is not based on changes in transcription (Bentzinger 
et al., 2005), but may be based on its immobilization in the 
  muscle basement membrane. As laminin-α5 does not bind to 
α-dystroglycan (Ido et al., 2004), it probably does not contribute 
to linking α-dystroglycan to basement membrane. However, 
laminin-α5 is not truncated at the N-terminal end, a site impor-
tant for the formation of the primary laminin scaffold. Thus, 
the increased concentration of LM-511 in the transgenic mice 
may be important for the restoration of muscle basement 
  membrane. We also observed a restoration of the amount of 
α-dystroglycan in mice that express the transgene (Fig. 7 and 
Fig. S3). This change was very striking when we used an affi  nity-
purifi   ed antiserum directed against the protein backbone of 
α-dystroglycan (Herrmann et al., 2000), but was not seen with 
the antibody IIH6 directed to the carbohydrate moiety (Gawlik 
et al., 2004; unpublished data). It may be possible that altera-
tions in the proteolytic processing of dystroglycan, may lead to 
the loss of the epitope recognized by the antipeptide antibody, 
whereas glycosylation is not affected.
Future directions in the development 
of a MDC1A treatment
We and others (Qiao et al., 2005) noticed that mini-agrin does 
not remove all of the symptoms. Laminin-α2 defi  ciency in 
nonmuscle tissue, particularly in the peripheral nerve, clearly JCB • VOLUME 176 • NUMBER 7 • 2007  990
contributes to the pathology in dy
W/dy
W mice, and because our 
transgenes are only expressed in muscle, the pathology in non-
muscle cells is not reversed. Interestingly, some symptoms are 
still present in dy
W/dy
W mice that express human laminin-α2 in 
skeletal muscle (Kuang et al., 1998), whereas amelioration is 
more complete in mice that express laminin-α1 under the con-
trol of the ubiquitously expressed chicken β-actin promoter 
(Gawlik et al., 2004). Thus, the exclusive expression of all our 
transgenes in muscle does contribute to the incompleteness of 
the amelioration. In addition, it is also probable that mini-
agrin cannot substitute all of the functions of laminin-α2. For 
example, mini-agrin is not known to bind to those integrins that 
are expressed in muscle, and thus, any function mediated by the 
binding of laminin-α2 to integrins cannot be compensated for. 
Several lines of evidence strongly suggest that binding of 
 laminin-α2 to α7β1 integrin is important to prevent anoikis 
(Vachon et al., 1996, 1997). As recent fi  ndings indicate that pre-
vention of apoptosis by genetic manipulation is also benefi  cial 
for  dy
W/dy
W mice (Girgenrath et al., 2004; Dominov et al., 
2005), it might be possible that antiapoptotic agents act syner-
gistically with mini-agrin. Several apoptosis inhibitors are used 
in clinical development. Thus, the combination of antiapoptotic 
drugs with the expression of mini-agrin in muscle, and/or the 
up-regulation of endogenous agrin, might be a promising ap-
proach to help MDC1A patients. Future experiments will be 
aimed at critically testing such a strategy.
Materials and methods
Generation of the constructs and transgenic mice
The m-mag cDNA was obtained by two independent RT-PCRs on mRNA 
isolated from mouse skeletal muscle. The 0.75-kb cDNA encoding the 
25-kD N-terminal agrin and the 2.2-kb cDNA encoding the 95-kD C-terminal 
half were ligated, and a 5× myc-tag (0.25 kb) was added to the 3′ end to 
yield the m-mag–myc (m-mag) construct. The 3.2-kb m-mag construct was 
sequenced and subcloned downstream of the uni-directional pTRE2 tet-
  responsive promoter (tetO7-CMV; BD Biosciences; pTRE2, 3.8 kb). A PacI 
site was inserted into the pTRE2 vector to allow linearization of the con-
struct as a 4.9-kb PacI–AseI fragment for injection into mouse oocytes. All 
transgenic mouse lines in which the cDNA was stably inserted into the ge-
nome were mated with transgenic mice expressing the tetracycline-dependent 
transcription activator (tTA) under the control of a 3.3-kb fragment of the 
human muscle CK (MCK) promoter (Fig. S1). MCK-tTA mice were obtained 
from N. Raben (National Institutes of Health, Bethesda, MD; Ghersa et al., 
1998) and were shown to drive expression of transgenes in skeletal and 
heart muscle (Ghersa et al., 1998; Raben et al., 2001). The AgPerl fusion 
protein was created by fusing the cDNA encoding the 0.75-kb 5′ region 
of chick agrin (Mascarenhas et al., 2003) with a cDNA coding for domain 
V of mouse perlecan (full-length cDNA encoding mouse perlecan was a gift 
from T. Sasaki, Max-Planck-Institut for Biochemistry, Martinsried, Germany). 
Both the 6.2-kb c-FLag and the 3.1-kb AgPerl were subcloned downstream 
of the 1.3-kb MCK promoter (Fig. S1, B–D). Constructs were linearized 
and injected into male pronuclei. C-mag transgenic mice (c-mag) were 
  created as previously described (Moll et al., 2001). dy
W/dy
W mice (Kuang 
et al., 1998) containing a LacZ insertion in the LAMA2 gene served as the 
mouse model for MDC1A.
Genotyping
Genotyping of heterozygous and homozygous dy
W/dy
W mice was done 
as previously described (Kuang et al., 1998). M-mag mice were geno-
typed by primers designed to amplify a 683-bp-long fragment, including 
the linker region of the N- and C-terminal parts of the m-mag construct 
(5′-G  C  G  G  A  T  C  A  C  T  T  T  G  C  G  G  A  A  C  C  -3′ and 5′-T  C  G  A  A  C  C  T  G  A  A  C  T  G  T  A  C  A-
T  G  A  C  C  -3′). Both c-FLag and c-mag mice were genotyped with primers 
amplifying a 591-bp-long fragment coding for the C-terminal part of agrin 
(5′-A  C  C  T  G  G  A  T  A  A  G  C  G  T  T  T  T  G  T  T  -3′ and 5′-C  T  T  C  T  G  T  T  T  T  G  A  T  G  C  T  C  A  G  C  -3′). 
Genotyping of AgPerl transgenic mice was performed on the chick agrin 
portion of the construct (5′-G  T  C  C  C  T  T  G  C  T  G  A  T  G  A  C  C  T  T  G  A  -3′, 5′-A  C  C  C-
A  G  C  C  C  C  T  C  A  G  T  A  C  A  T  G  T  -3′). To distinguish hemi- from homozygous 
MCK-tTA mice, we performed quantitative TaqMan PCR (TaqMan PCR 
core reagent kit; Applied Biosystems) on the genomic DNA. The following 
primers were used: tTA-transgene, 5′-G  C  C  T A  C  A T  T  G  T A T  T  G  G  C  A T  G  T A  A  A  A  -3′, 
5′-C  A  A  A  A  G  T  G  A  G  T  A  T  G  G  T  G  C  C  T  A  T  C  T  A  A  C  A  -3′, and Probe 5′-FAM-
C  T  T  T  G  C  T  C  G  A  C  G  C  C  T  T  A  G  C  C  A  T  T  G  A  G  -TAMRA 3′. For normalization of 
copy number, the following probes for β-actin were used: 5′-C  C  A  C  T-
G  C  C  G  C  A  T  C  C  T  C  T  T  -3′, 5′-G  C  T  C  G  T  T  G  C  C  A  A  T  A  G  T  G  A  T  G  A  C  -3′, and Probe 
5′-FAM-C  C  C  T  G  G  A  G  A  A  G  A  G  C  T  A  T  G  A  G  C  T  G  C  C  T  G  -TAMRA-3′.
Regulation of the tet-off system
For temporal regulation of m-mag expression under the tetracycline-regulated 
tet-off expression system (Gossen and Bujard, 1992), 5 μg doxycycline 
(doxycycline hydrochloride; Sigma-Aldrich) per milliliter of drinking water 
(enriched by 4% sucrose) was administered in dimmed bottles. For repres-
sion after transgene expression, 50 μg of doxycycline per milliliter of drink-
ing water was applied.
Protein production
The cDNAs encoding m-mag or AgPerl were subcloned into the pCEP-Pu 
vector (Kohfeldt et al., 1997) and transfected into HEK 293 EBNA cells. 
Conditioned medium was collected, and the relative amount of the protein 
was determined by dot blot assays. Such supernatants were directly used 
for experiments.
Solid-phase binding assays
96-well plates were coated with either chick α-dystroglycan enriched from 
skeletal muscle as previously described (Gesemann et al., 1998) or with 
laminin-111 (0.5 μg/well), which was a gift from J. Engel (Biozentrum, 
University of Basel, Switzerland). Proteins were coated in 50 mM sodium 
carbonate buffer, pH 9.6, and incubated overnight at 4°C. After blocking 
with PBS containing 0.05% Tween-20, 1 mM CaCl2, 1 mM MgCl2, and 
3% BSA (blocking buffer), wells were incubated with a dilution series (1:6) 
of supernatant containing m-mag (pure supernatant as the starting concen-
tration) or of puriﬁ  ed c-mag (50 nM as the starting concentration). The 
wells were washed with blocking buffer. Bound protein was detected with 
polyclonal antibodies raised against the C-terminal, 95-kD part of chick or 
mouse agrin. Alternatively, the monoclonal antibody 9E10 (Evan et al., 
1985) directed against the myc-tag was used. For detection, appropriate 
horse radish peroxidase–conjugated antibodies, followed by McEvans so-
lution, ABTS, and H2O2, were used. The absorbance was measured on an 
ELISA reader at 405 nm after 15 min.
Overlay assays
Lysates enriched for α-dystroglycan were obtained from chick or mouse 
skeletal muscles, as previously described (Gesemann et al., 1998). Pro-
teins were separated on a 3–15% SDS gel and blotted to nitrocellulose 
membrane. Blots were blocked for 2 h with PBS containing 0.05% Tween-20, 
1 mM CaCl2, 1 mM MgCl2, and 5% dry milk powder (blocking buffer). 
  Supernatants containing recombinant proteins were added and incubated 
overnight at 4°C. After several washes with blocking buffer, bound m-mag 
was detected with the anti-myc antibody 9E10, whereas   detection of 
  AgPerl was done using a polyclonal antiserum raised against the N-terminal 
part of agrin. For detection, appropriate horse radish   peroxidase–
  conjugated antibodies were used, and immunoreactivity was visualized by 
the ECL detection method (Pierce Chemical Co.).
Immunoblots
Tissues were homogenized in protein extraction buffer (75 mM Tris-HCl, 
pH 6.8, 3.8% SDS, 4 M urea, 20% glycerol, and 5% β-mercaptoethanol). 
Equal amounts of protein were separated on a 3–12% SDS–PAGE and 
  immunoblotted. Protein signals were normalized to β-actin (Santa Cruz 
Biotechnology; sc-8432) or β-tubulin (BD Bioscience).
Northern blot analysis and quantitative TaqMan PCR
Northern blot assays were performed on total RNA extracted from skel-
etal muscles using Northern Max Kit (Ambion). Signals were normal-
ized to corresponding β-actin signals. Quantitative TaqMan PCR was 
performed on the m-mag transgene (5′-T  G  T  G  C  C  A  A  T  G  T  G  A  C  C  G  C  T  A  -3′, 
5′-G  C  T  G  A  A  A  C  C  C  T  T  G  C  C  A  G  A  A  -3′, and Probe 5′-FAM-C  C  C  C  C  A  A  A  G  T  C-
C  T  G  T  G  A  T  T  C  C  C   -TAMRA 3′) and was normalized to β-actin (5′-C  C  A  C  T  G-
C  C  G  C  A  T  C  C  T  C  T  T  -3′, 5′-G  C  T  C  G  T  T  G  C  C  A  A  T  A  G  T  G  A  T  G  A  C  -3′, and Probe 
5′-FAM-C  C  C  T  G  G  A  G  A  A  G  A  G  C  T  A  T  G  A  G  C  T  G  C  C  T  G  -TAMRA-3′).AMELIORATION OF LAMININ-𝗂2 DEFICIENCY • MEINEN ET AL. 991
Locomotion, muscle strength, and CK assay
Locomotive behavior was determined as previously described (Moll et al., 
2001). In brief, mice were placed into a new cage and motor activity 
(walking, digging, and standing upright) was measured for 10 min. Grip 
strength was evaluated by placing the animals onto a vertical grid and 
measuring the time until they fell down. The cut-off time was 3 min. Blood 
for CK assays was collected from the tail vein. 2 μl of serum was applied 
using the CK CK-NAC Liqui-UV kit (Rolf Greiner Biochemica). In all tests, at 
least three animals of each genotype were analyzed, and values were nor-
malized to values obtained from WT animals.
Histology, immunohistochemistry, and antibodies
Muscles were immersed in 7% gum tragacanth (Sigma-Aldrich) and rap-
idly frozen in liquid nitrogen–cooled isopentane (–150°C). 12-μm-thick 
cross sections or longitudinal sections were cut and collected on Super-
Frost Plus slides (Menzel-Glaser). In the case of longitudinal sections, the 
slides were pretreated with 3% aqueous EDTA. General histology was 
performed using HE (Merck). Masson’s Trichrome staining (Luna, 1968) 
was used to visualize collagenous tissue. Membrane-bound and extracel-
lular epitopes were visualized with Alexa Fluor 488  –conjugated WGA 
(Invitrogen). Polyclonal rabbit anti–mouse laminin-α5 (Ab 405) and mono-
clonal rat anti–mouse laminin-α1 (Ab 198; Sorokin et al., 1992) were a 
gift from L. Sorokin (Lund University, Lund, Sweden). Polyclonal sheep 
anti–mouse α-dystroglycan was a gift from S. Kröger (University of Mainz, 
Mainz, Germany). The remaining antibodies were produced in-house or 
obtained as follows: monoclonal mouse anti–rat dMyHC (Novocastra), 
monoclonal rat anti–mouse laminin-γ1 chain (CHEMICON International, 
Inc.), polyclonal rabbit anti–chick (produced in-house; Gesemann et al., 
1995), and anti–mouse agrin (produced in-house). Mouse monoclonal 
anti-myc antibody (9E10) was produced and puriﬁ  ed from hybridoma cell 
line 9E10 and was biotinylated (D-Biotinoyl-E-aminocaproic acid-N-
  hydroxysuccinimidester; Roche). Depending on the source of the primary 
antibody, appropriate Cy3-conjugated (Jackson ImmunoResearch Labora-
tories) Alexa Fluor 488–conjugated secondary antibodies (Invitrogen) or 
TRITC-labeled streptavidin were used for visualization. DAPI was used to 
stain nuclei.
Quantiﬁ  cation of immunostainings
The muscle ﬁ  ber size was quantiﬁ  ed using the minimum distance of parallel 
tangents at opposing particle borders (minimal “Feret’s diameter”), as pre-
viously described (Briguet et al., 2004). Pictures of WGA-stained cross 
sections were collected using a ﬂ   uorescence microscope (DM5000B; 
Leica), a digital camera (F-View; Soft Imaging System), and analySIS soft-
ware (Soft Imaging System). Measurement of minimal Feret’s diameter of 
notexin-treated muscle was done on cross sections stained for laminin-γ1 
and dMyHC. Normalization of the number of ﬁ  bers in each ﬁ  ber Feret 
class of 5 μm was based on the total number of muscle ﬁ  bers in each pic-
ture. Fibrosis was quantiﬁ   ed by measuring the ﬁ   brotic area of WGA-
stained muscle cross section and normalizing it to the entire area of 
the cross section. For quantiﬁ  cation of immunostainings of m-mag, c-mag, 
c-FLag, laminin-α5, or α-dystroglycan, images were collected and ana-
lyzed by a confocal microscope (TCS-8P; Leica) and appropriate software. 
InSpeck Microscope Image Intensity Calibration kit (Invitrogen) was used to 
determine the linear range of the laser. Speciﬁ  c intensity was calculated for 
each image as the signal intensity of the muscle circumference minus that 
of an adjacent, nonstained region (Turney et al., 1996). Five different pic-
tures were taken using the same parameters on each section, and four dif-
ferent sections were used for each individual mouse. In all quantiﬁ  cation 
experiments, at least three mice of each genotype were analyzed.
Evaluation of full-length agrin expression
Transgenic c-mag and c-Flag were detected by the polyclonal rabbit anti–
chick agrin (Gesemann et al., 1995). For comparison of the transgenic 
m-mag and the endogenous agrin, an antiserum recognizing the 95-kD, 
C-terminal half of mouse agrin was used. Chick and mouse agrin immuno-
stainings were quantiﬁ  ed separately, as described in the previous section. 
Under the premise that c- and m-mag ameliorate the disease phenotype to 
the same extent, the relative expression levels of both were set to 100%. 
This clearly shows that levels of endogenous agrin expressed in kidney 
(expression level, 113% of m-mag) are sufﬁ  cient to at least produce the 
ameliorating effect of c-Flag (expression level, 81% of c-mag).
Notexin-induced muscle damage
Tibialis anterior of 5-wk-old mice was injured by injection of 15–20 μl 
notexin (50 μg/ml; Sigma-Aldrich), as previously described (Bentzinger 
et al., 2005). Mice were killed 6, 14, or 28 d after injection, and mus-
cles were isolated and processed as described in Quantiﬁ   cation of 
immunostainings.
Hydroxyproline assay
Fibrosis in triceps brachii muscles was measured by assaying for the 
exclusive collagen-speciﬁ  c modiﬁ  ed aminoacid hydroxyproline (Woessner, 
1961; Edwards and O’Brien, 1980). Tendons were carefully removed be-
fore muscles were vacuum-speed dried and sent to Analytical Research 
Services (Bern, Switzerland) for amino acid analysis. There, each muscle 
was hydrolyzed under vacuum in 50 μl of 6 N HCl for 22 h at 115°C. 
  Hydrolysates were evaporated to dryness and resuspended in 0.1% triﬂ  uoro-
acetic acid. Aliquots were diluted 1:100 for determination of amino acids 
by a routine method (Cohen et al., 1986), including derivatization with 
phenylisothiocyanate, followed by HPLC, identifying, and quantifying 
the collagen-related amino acid hydroxyproline. Relative hydroxyproline 
amount was assessed in reference to the total amount of amino acids.
Statistical analysis
To compare the different genotypes, p-values were calculated using the 
  unpaired two-sample t-tests, assuming equal variances.
Online supplemental material
Fig. S1 represents the regulation of expression by the inducible tetra  cycline-
regulated tet-off expression system (Gossen and Bujard, 1992) and the 
breeding scheme to obtain dy
W/dy
W mice with a tight spatial and tempo-
ral regulation of mini-agrin expression. Fig. S2 shows the binding of the 
transgenic m-mag and the fusion protein AgPerl to laminin and α-dystroglycan 
in both solid-phase and overlay binding assays. In Fig. S3, immunohisto-
chemical staining of cross sections visualizes the regulation of different 
agrin-binding proteins, including laminin-α5, α-dystroglycan, and laminin-α1 in 
dy
W/m-mag mice. The online version of this article is available at http://
www.jcb.org/cgi/content/full/jcb.200611152/DC1.
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